Trial Profile
Pharmacokinetic Enhancement of Crizotinib plasma concentrations with Cobicistat or Itraconazole in Anaplastic Lymphoma Kinase positive advanced Non-Small Cell Lung Cancer Patients - PrECIsioN
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary) ; Cobicistat; Itraconazole
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Acronyms PrECIsioN
- 04 May 2017 New trial record